# A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

> **NCT07019883** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 80 (actual)

## Conditions studied

- Avian Influenza

## Interventions

- **BIOLOGICAL:** H5 AC-Anhui RNA Vaccine
- **BIOLOGICAL:** H5 Astrakhan RNA Vaccine
- **OTHER:** Sodium Chloride, 0.9%

## Key facts

- **NCT ID:** NCT07019883
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07019883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07019883, "A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07019883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*